Could a lighter chemo combo work for some breast cancer patients?
NCT ID NCT07271992
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests a less intense treatment for people with early-stage triple-negative breast cancer. It combines two drugs, sacituzumab govitecan and tislelizumab, to see if they can shrink tumors before surgery. The goal is to find out which patients can safely use this milder approach based on specific markers in their tumors. About 30 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.